By Pankaj Mondal, DrugPatentWatch writer Machine learning, the most fundamental form of artificial intelligence, has started infiltrating the medical field, and it seems machines can play a crucial role in…
Posts published in “Insights”
By Ed Lamb, DrugPatentWatch writer Under a new commissioner dedicated to bolstering competition to reduce prices, the agency is redoing a raft of rules and guidances to speed ANDA approvals…
The FDA was established to ensure the safety of food and medicines sold in the US. Sadly, the original charter is now slowly being affected by the advocates of drug…
This article was originally published by Jingyun Ni, Junrui Zhao, Carolina Oi Lam Ung, Yuanjia Hu, Hao Hu and Yitao Wang in Globalization and Health201713:21 under a Creative Commons License. Abstract…
Giving Drugs a Second Chance: Overcoming Regulatory and Financial Hurdles in Repurposing Approved Drugs As Cancer Therapeutics
0
Originally published by J. Javier Hernandez, Michael Pryszlak, Lindsay Smith, Connor Yanchus, Naheed Kurji, Vijay M. Shahani and Steven V. Molinski in Front. Oncol., 14 November 2017. Abstract The repositioning or…
Biotechnology is a massive scientific field that uses research tools from biology and chemistry to solve problems and that includes human diseases too. Ever since its existence, it has revolutionized…
As pharmaceutical companies face ceaseless pressure to expedite products to market, strategies for improving the drug development and manufacturing process gets critical. And all challenges related to drug development start…
Originally published by Er J. Wouters, Panos G. Kavanos, Martin McKee in The Milbank Quarterly, 95: 554–601 under a Creative Commons License. Abstract Policy Points: Our study indicates that there are opportunities…
This article was originally published by Ekaterina Galkina Cleary, Jennifer M. Beierlein, Navleen Surjit Khanuja, Laura M. McNamee and Fred D. Ledley in PNAS under a Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC…
Without a strong biosimilars market, costs for biologics in the US continue trending upward. The world of drug patents for biosimilars in the United States is far more complex than…